Nautilus Bio Stock (NASDAQ:NAUT)

Forecast Ownership Financials Chart Transcripts

Previous Close

$0.71

52W Range

$0.62 - $3.09

50D Avg

$0.73

200D Avg

$1.14

Market Cap

$89.20M

Avg Vol (3M)

$329.97K

Beta

1.24

Div Yield

-

NAUT Company Profile

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

134

IPO Date

Aug 07, 2020

Website

NAUT Performance

NAUT Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	-	$-76.15M	$-63.62M
Net Income	$-70.78M	$-63.67M	$-63.74M
EBITDA	-	$-74.30M	$-54.51M
Basic EPS	$-0.56	$-0.51	$-0.51
Diluted EPS	$-0.56	$-0.51	$-0.51

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q2 25Aug 01, 25 | 8:30 AM

Q1 25Apr 29, 25 | 8:30 AM

Q4 24Feb 28, 25 | 8:30 AM

Peer Comparison

Ticker	Company
HCWB	HCW Biologics Inc.
MNOV	MediciNova, Inc.
QSI	Quantum-Si incorporated
SEER	Seer, Inc.
NRIX	Nurix Therapeutics, Inc.
HUMA	Humacyte, Inc.
CRBU	Caribou Biosciences, Inc.